Tidemark’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Tidemark’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.5K	Buy	1,407 +18	+1%	+$540	0.01%	314
2026 Q1	$40.4K	Sell	1,389 -8	-0.6%	-$232	0.01%	293
2025 Q4	$36.6K	Buy	1,397 +2	+0.1%	+$51	0.01%	275
2025 Q3	$32.9K	Buy	1,395 +48	+4%	+$1.06K	0.01%	297
2025 Q2	$27.6K	Sell	1,347 -74	-5%	-$1.49K	0.01%	323
2025 Q1	$29.1K	Buy	1,421 +152	+12%	+$3.39K	0.01%	309
2024 Q4	$28.7K	Buy	1,269 +243	+24%	+$5.83K	0.01%	309
2024 Q3	$25.3K	Hold	1,026	–	–	0.01%	304
2024 Q2	$23.7K	Buy	+1,026	New	+$24K	0.01%	302
2024 Q1	–	Sell	-181	Closed	-$4.16K	–	717
2023 Q4	$4.16K	Buy	+181	New	+$3.64K	﹤0.01%	527

Other funds holding IDNA

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tidemark's IDNA Position: Q2 2026 in Review

Tidemark increased its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 1.3% in Q2 2026, buying an estimated $540 and bringing the position to 1,407 shares worth $47.5K. The position accounts for 0.01% of the portfolio, ranked #314.

Tidemark first reported a position in IDNA in Q4 2023 and has held it in 10 quarters since. 66 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

Tidemark held 1,407 shares of iShares Genomics Immunology and Healthcare ETF worth $47.5K as of Q2 2026.
Tidemark bought 18 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $540.
iShares Genomics Immunology and Healthcare ETF made up 0.01% of Tidemark's portfolio in Q2 2026, its #314 holding.
Tidemark first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2023 and has held it in 10 quarters since.
66 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.